Goldman Sachs Upgrades Onyx Pharmaceuticals to CL-Buy
Goldman Sachs has upgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Buy to CL-Buy and has added the company to its Americas Conviction List. Price target has been raised from $45 to $47.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.